Return to Press Releases View Archived

October 24, 2008

NUCRYST Pharmaceuticals to Release Third Quarter 2008 Financial Results on Thursday, November 6, 2008

WAKEFIELD, MA, October 24, 2008 -- NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS), a developer and manufacturer of medical products that fight infection and inflammation, announced plans to release its financial results for the third quarter 2008 on Thursday, November 6, 2008. The company will host a conference call at 9:00 AM ET on Friday, November 7, 2008 to discuss the financial results for the quarter.

Conference call details:
Date:            Friday, November 7, 2008
Time:            9:00 AM ET
Dial-in:         866.578.5747 (U.S.) 
                    617.213.8054 (International)
Passcode:   50533222 
Web cast:    http:\\www.nucryst.com (Investor Relations section)
 
An audio replay of the call will be available for 7 days:
Access:       888-286-8010 (U.S.) 
                     617-801-6888 (International)
                     Replay Passcode: 74057266

In addition to the standard disclosure over wire services, a news release and financial statements will be posted on the NUCRYST website.

About NUCRYST Pharmaceuticals

NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes medical products that fight infection and inflammation using SILCRYST™, its patented atomically disordered nanocrystalline silver technology.   NUCRYST licensed world-wide rights for SILCRYST™ wound care coating products to Smith & Nephew plc, which markets these products in over 30 countries under their Acticoat™ trademark.  NUCRYST is also developing pharmaceutical products to address medical conditions that are characterized by pain, infection and inflammation.   The Company has developed its proprietary nanocrystalline silver in a powder form, referred to as NPI 32101 for use in medical devices and as an active pharmaceutical ingredient.
 
For more information, contact:
David B. Holtz
Vice President and Chief Financial Officer
NUCRYST Pharmaceuticals Corp.
781.224.1444
info@nucryst.com

Fern Lazar
Lazar Partners
212.867.1762

Acticoat™ is a trademark of Smith & Nephew plc
SILCRYST™ is a trademark of NUCRYST Pharmaceuticals Corp.

Return to Press Releases View Archived